Pulmonary function tests measure airflow, lung volume and gas transfer. They can describe a baseline or change in function, while clinical assessment identifies its cause.
A full set has three parts. Spirometry has the person breathe in fully and blow out as hard and as long as possible, measuring the forced vital capacity (FVC) and how fast air leaves; the forced expiratory volume in one second (FEV1) and its ratio to FVC are the usual numbers. The ATS/ERS 2019 spirometry standard describes the test as the maximal volume of air a person can inspire and expire with maximal effort, reports FEV1/FVC as a decimal fraction, and sets acceptability and repeatability criteria for each manoeuvre, so a poor-effort test is a quality problem before it is a finding. Spirometry is used to look for obstructive conditions, in which the airways narrow so air flows out with difficulty, as in asthma, bronchitis and emphysema (MedlinePlus). A lung volume test, often done by body plethysmography in a sealed booth, measures the total lung capacity (TLC), the amount of air the lungs can hold; restrictive conditions, in which the lungs cannot fill fully, such as pulmonary fibrosis and interstitial lung disease, lower it. The diffusing capacity for carbon monoxide (DLCO) has the person breathe in a gas mixture with a trace of carbon monoxide and a tracer gas, hold the breath for about 10 seconds and breathe out; it shows how well gas crosses into the blood. The ERS/ATS 2022 interpretation standard explains that a low DLCO with normal alveolar volume can be consistent with pulmonary vascular impairment, emphysema with preserved volume or anaemia. Low alveolar volume with low or normal transfer coefficient can accompany interstitial lung disease or emphysema with loss of lung volume. These are patterns to interpret, not diagnoses from one value. The 2017 ERS/ATS standard asks for no smoking or other carbon-monoxide exposure on the day of the test, recording the last cigarette and accounting for recent or heavy exposure. Its preparation instructions are technical test conditions, not an individual treatment plan.
How a result is judged. A value is compared with a healthy reference population for the person's age, sex and height. The ERS/ATS 2022 technical standard defines the lower limit of normal as the 5th percentile, a z-score of minus 1.645, so 5 per cent of a healthy reference population lie below that limit by definition. It strongly discourages the fixed cut-offs of 80 per cent of predicted for FEV1 and 0.70 for the FEV1/FVC ratio, because percent of predicted ignores how measurement variability changes with age, and it adds the qualifier that neither simple cut-offs nor the 5th percentile should be used as absolute diagnostic criteria, since healthy and diseased values overlap in a zone of uncertainty. Ideally the comparison is with the person's own earlier baseline. Serial results need their test quality, measurement variability and clinical context. A threshold developed for another test or population should not be turned into a universal DLCO monitoring rule. For DLCO the standard says the importance of haemoglobin cannot be overemphasised and all interpretations must have the reference values adjusted for haemoglobin, with particular care when people are monitored for drug toxicity and haemoglobin shifts, as in chemotherapy. A 2024 transplant cohort report likewise states that DLCO is affected by haemoglobin and that two adjustment equations (Cotes, recommended by ATS/ERS, and Dinakara) gave different results, so the method should be named.
Their place in drug-related lung injury. A baseline records a person's own starting point, which makes a later change easier to read than a comparison with a population average. In diagnosis the tests are one input: an Italian multidisciplinary expert-opinion panel on drug-induced interstitial lung disease lists spirometry and DLCO among the diagnostic components alongside history, vital signs including oxygen saturation, laboratory and microbial tests to exclude infection, and computed tomography, stratifies management by CTCAE grade, and notes that there were no specific guidelines at the time (Conte et al., 2022). In follow-up, repeat testing can show whether function is recovering or worsening. They do not replace imaging: the trastuzumab deruxtecan label asks for symptom monitoring and radiographic evaluation of suspected interstitial lung disease, and neither it nor the datopotamab deruxtecan label mentions scheduled breathing tests. For scale, adjudicated drug-related interstitial lung disease occurred in 12.1 per cent of patients given trastuzumab deruxtecan in DESTINY-Breast04, 0.8 per cent grade 5 (Modi et al., 2022), and a prior lung event can bear on eligibility for later treatment. A test pattern does not identify cause, since many conditions lower DLCO; that normal spirometry does not rule out interstitial disease is an evidence-reading distinction between airflow and gas transfer; the 2022 standard also states that a result within the reference range does not exclude disease.
Shares Radiation pneumonitis and lung fibrosis, Pneumonitis, Interstitial lung disease (ILD) / pneumonitis.
Shares Pneumonitis, Interstitial lung disease (ILD) / pneumonitis.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/